

HIFI Study: HIFU vs Radical prostatectomy in the curative treatment of localized prostate cancer GG 1 & 2: Intermediate carcinologic results at 2 years



ClinicalTrials.gov NCT04307056

21-4245

P. Rischmann, B. Occean, A.Villers, N.Houede, X.Rebillard, A.Gelet, T.Chevallier, P. Coloby and HiFi Group investigators

Method

Multicentre, prospective, non randomized, comparative study

<u>Treatments</u>: <u>HIFU</u>: total or subtotal (≥ 70% prostate volume)

Focal One®, Edap tms ™, Vaux en Velin - France

Inclusion criteria RP: robotic, laparoscopic, open

T1-2 NxM0, GG 1 (non eligible for AS) and GG 2, Gleason score ≤ 7, restricted to the form [3 + 4], PSA < 15 ng/mL, mpMRI

Primary endpoint:

Survival rate without Salvage Treatment (SST)

Secondary endpoints:

PSA, PM, biological recurrence, positive biopsies, metas, specific and overall survival

Patients

Treated patients: 1988 HIFU / 1380 RP

Age: 75.2 in HIFU group / 64.4 in RP group


GG1/2: 41%/59% in HIFU group / 37% / 63% in RP group

PSA: 7.1 ng/mL in HIFU group / 6.9 in RP group

Results

Primary endpoint: Survival rate without salvage treatment at 24 months

	Event	Hazard Ratio (95% CI)	Survival Estimates (95% CI)	p-value
HIFU	69	0.23 (0.16-0.33)	98.0 (97.3-98.7%)	<.0001
RP	134	Reference	91.9 (90.3-93.5%)	



- Secondary endpoints :
 - **PSA nadir**: 0.34 in HIFU group / 0.01 in RP group
 - **Positive margins after RP**: 277/1301 (24%)
 - Biological recurrence (BR) after HIFU: 202 /1224 (16.5%)
 - Biopsies after HIFU: Only 13.2 % of for-cause biopsies
 - Salvage tt: 2RP + 65Rxtt + 2AB

Conclusion

Apparent superiority of HIFU (Focal One®, Edap tms ™) on RP according to these intermediate data on 3368 patients HIFU SST: 95% VS RP SST 87%, PM after RP: 24%, Radiation therapy often indicated for PM, BR after HIFU: 16.5% Data not yet consolidated at 2 years: 30 months follow-up is necessary